Celgene

Celgene Corporation
Company typeSubsidiary
Nasdaq: CELG
IndustryBiotechnology
Founded1986; 38 years ago (1986)
FounderSol J. Barer
HeadquartersSummit, New Jersey, U.S.
Key people
Robert J. Hugin (executive chairman)
Mark Alles (CEO)
ProductsRevlimid
Abraxane
Pomalyst/Imnovid
Thalomid
Idhifa
RevenueIncrease $15.281 billion (2018)
Increase $4.046 billion (2018)
Total assetsIncrease $35.480 billion (2018)
Total equityDecrease $6.161 billion (2018)
Number of employees
8,852 (2018)
ParentBristol Myers Squibb
Websitewww.bms.com
Footnotes / references
[1]

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).[2]

  1. ^ "Celgene Corporation 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. ^ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020